| Original language | English |
|---|---|
| Pages (from-to) | 930-935 |
| Number of pages | 6 |
| Journal | Kidney International |
| Volume | 102 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2022 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Kidney International, Vol. 102, No. 4, 10.2022, p. 930-935.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
AU - ICPi-AKI Consortium
AU - Gupta, Shruti
AU - Strohbehn, Ian A.
AU - Wang, Qiyu
AU - Hanna, Paul E.
AU - Seethapathy, Rituvanthikaa
AU - Prosek, Jason M.
AU - Herrmann, Sandra M.
AU - Abudayyeh, Ala
AU - Malik, A. Bilal
AU - Loew, Sebastian
AU - Carlos, Christopher A.
AU - Chang, Wei Ting
AU - Beckerman, Pazit
AU - Mithani, Zain
AU - Shah, Chintan V.
AU - Renaghan, Amanda D.
AU - de Seigneux, Sophie
AU - Campedel, Luca
AU - Kitchlu, Abhijat
AU - Shin, Daniel Sanghoon
AU - Coppock, Gaia
AU - Lumlertgul, Nuttha
AU - Garcia, Pablo
AU - Ortiz-Melo, David I.
AU - Rashidi, Arash
AU - Sprangers, Ben
AU - Aggarwal, Vikram
AU - Benesova, Karolina
AU - Jhaveri, Kenar D.
AU - Cortazar, Frank B.
AU - Weins, Astrid
AU - Zuo, Yiqin
AU - Mooradian, Meghan J.
AU - Reynolds, Kerry L.
AU - Leaf, David E.
AU - Sise, Meghan E.
AU - Salem, Joe Elie
AU - Bagnis, Corinne Isnard
AU - Singh, Harkarandeep
AU - Motwani, Shveta S.
AU - Murakami, Naoka
AU - Tio, Maria C.
AU - Mothi, Suraj S.
AU - Selamet, Umut
AU - Schmidt-Ott, Kai M.
AU - Chang, Weiting
AU - Wanchoo, Rimda
AU - Madhavan, Sethu M.
AU - Owen, Dwight H.
AU - Husain, Marium
N1 - Funding Information: SG receives research funding from GE Healthcare and BTG International and is president and founder of the American Society of Onconephrology. KDJ is a consultant for Astex Pharmaceuticals, Natera, GlaxoSmithKline, ChemoCentryx, and Chinook; a paid contributor to Uptodate.com; receives honorarium from the International Society of Nephrology and the American Society of Nephrology; and is cofounder and copresident of the American Society of Onconephrology. DSS participates in the speakers’ bureau at Genentech. FBC is a consultant for ChemoCentryx and Retrophin. AA is supported by the Division of Internal Medicine Immuno-Oncology Toxicity Award Program of the University of Texas MD Anderson Cancer Center. BS is a senior clinical investigator at the Research Foundation Flanders (F.W.O.) (1842919N) and is supported by Stichting tegen Kanker (grant C/2020/1380). AR is a consultant for Otsuka Pharmaceutical Company and treasurer of the American Society of Onconephrology. SMH is supported by the Mayo Clinic K2R award. KB receives grant support from the Olympia Morata Programme, Foundations Commission of University of Heidelberg, Rheumaliga Baden-Württemberg e.V., Abbvie, and Novartis; and also serves as a consultant for and receives speaker fee/travel reimbursements from Abbvie, BMS, Janssen, MSD, Viatris, Gilead/Galapagos, Janssen, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche, and Union Chimique Belge. MES has served on a scientific advisory board for Mallinckrodt. MJM has served as a consultant or received honorarium from AstraZeneca, Immunai, Istari Oncology, Nektar Therapeutics, and Bristol Myers Squibb. LC serves as a consultant for and receives honorarium and/or travel reimbursements from Pfizer, Bristol Myers Squibb, and MSD. All other authors declared no competing interests.
PY - 2022/10
Y1 - 2022/10
UR - https://www.scopus.com/pages/publications/85136628168
U2 - 10.1016/j.kint.2022.07.019
DO - 10.1016/j.kint.2022.07.019
M3 - Article
C2 - 35964800
AN - SCOPUS:85136628168
SN - 0085-2538
VL - 102
SP - 930
EP - 935
JO - Kidney International
JF - Kidney International
IS - 4
ER -